Inamed
This article was originally published in The Gray Sheet
Executive Summary
McGhan Medical subsidiary's round saline breast implants used for augmentation will cost 12% more as of Sept. 15, parent company Inamed says in an Aug. 7 release. The price hike is the first in five years and may affect third quarter financials depending on the reaction of customers and competitors, according to company President and CEO Ilan Reich. Recent speculation over breast implant price erosion has raised concern on Wall Street (1"The Gray Sheet" July 31, p. 7)
You may also be interested in...
Inamed Finalizing Lap-Band Treatment IDE Plans, Collecting Three-Year Data
Inamed is expecting to hear from FDA within the next few weeks about expanding its Lap-Band obesity treatment training program under a treatment investigational device exemption, President and co-CEO Ilan Reich told a July 25 teleconference announcing second-quarter financial results.
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.